Chrysin enhances doxorubicin-induced cytotoxicity in human lung epithelial cancer cell lines: The role of glutathione

Toxicology and Applied Pharmacology

Volumn 258, Issue 1, 2012, Pages 1-9

  Brechbuhl, Heather M ^b   Kachadourian, Remy ^b   Min, Elysia ^b   Chan, Daniel ^a   Day, Brian J ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

Author keywords

Adriamycin; Chrysin; Flavonoids; Glutathione; Multidrug resistance proteins; Non small cell carcinoma

Indexed keywords

CHRYSIN; DOXORUBICIN; GLUTATHIONE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 5;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; LUNG NON SMALL CELL CANCER; PROTEIN EXPRESSION;

ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FLAVONOIDS; GLUTATHIONE; HUMANS; LUNG NEOPLASMS; P-GLYCOPROTEINS; TUMOR CELLS, CULTURED;

EID: 84855470386     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.08.004     Document Type: Article

References (55)

1. Awasthi S., Singhal S.S., Singhal J., Cheng J., Zimniak P., Awasthi Y.C. Role of RLIP76 in lung cancer doxorubicin resistance: II. Doxorubicin transport in lung cancer by RLIP76. Int. J. Oncol. 2003, 22:713-720.
2. Bailey H.H. L-S, R-buthionine sulfoximine: historical development and clinical issues. Chem. Biol. Interact. 1998, 111-112:239-254.
3. Bailey H.H., Mulcahy R.T., Tutsch K.D., Arzoomanian R.Z., Alberti D., Tombes M.B., Wilding G., Pomplun M., Spriggs D.R. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J. Clin. Oncol. 1994, 12:194-205.
4. Bailey H.H., Ripple G., Tutsch K.D., Arzoomanian R.Z., Alberti D., Feierabend C., Mahvi D., Schink J., Pomplun M., Mulcahy R.T., Wilding G. Phase I study of continuous-infusion L-S, R-buthionine sulfoximine with intravenous melphalan. J. Natl. Cancer Inst. 1997, 89:1789-1796.
5. Brechbuhl H.M., Gould N., Kachadourian R., Riekhof W.R., Voelker D.R., Day B.J. Glutathione transport is a unique function of the ATP-binding cassette protein ABCG2. J. Biol. Chem. 2010, 285:16582-16587.
6. Brunati, A. M., Pagano, M. A., Bindoli, A., and Rigobello, M. P. Thiol redox systems and protein kinases in hepatic stellate cell regulatory processes. Free Radic Res 44, 363-378.
7. Calcagno A.M., Fostel J.M., To K.K., Salcido C.D., Martin S.E., Chewning K.J., Wu C.P., Varticovski L., Bates S.E., Caplen N.J., Ambudkar S.V. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. Br. J. Cancer 2008, 98:1515-1524.
8. Calvert P., Yao K.S., Hamilton T.C., O'Dwyer P.J. Clinical studies of reversal of drug resistance based on glutathione. Chem. Biol. Interact. 1998, 111-112:213-224.
9. Circu, M. L., and Aw, T. Y. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med48, 749-762.
10. Cole S.P., Deeley R.G. Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol. Sci. 2006, 27:438-446.
11. Dean M. The Human ATP-Binding Cassette (ABC) Transporter Superfamily. The NCBI handbook [Internet] 2002, National Library of Medicine (US), National Center for Biotechnology Information, Bethesda (MD), Oct. 2002 Available from. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Books.
12. Dean M. The Human ATP-Binding Cassette (ABC) Transporter Superfamily 2002, National Library of Medicine (US); NCBI Bookshelf, Bethesda, MD.
13. Estrela J.M., Ortega A., Obrador E. Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci. 2006, 43:143-181.
14. Folmer Y., Schneider M., Blum H.E., Hafkemeyer P. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs. Cancer Gene Ther. 2007, 14:875-884.
15. Frischer H., Ahmad T. Severe generalized glutathione reductase deficiency after antitumor chemotherapy with BCNU" [1,3-bis(chloroethyl)-1-nitrosourea]. J. Lab. Clin. Med. 1977, 89:1080-1091.
16. Gaudet R. The ABCs of trans(porter) inhibition. Nat. Chem. Biol. 2008, 4:454-455.
17. Gerber S., Comellas-Bigler M., Goetz B.A., Locher K.P. Structural basis of trans-inhibition in a molybdate/tungstate ABC transporter. Science (New York, N.Y.) 2008, 321:246-250.
18. Giles G.I. The redox regulation of thiol dependent signaling pathways in cancer. Curr. Pharm. Des. 2006, 12:4427-4443.
19. Grant C.E., Gao M., DeGorter M.K., Cole S.P., Deeley R.G. Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab. Dispos. 2008, 36:2571-2581.
20. Helal G.K., Helal O.K. Metallothionein attenuates carmustine-induced oxidative stress and protects against pulmonary fibrosis in rats. Arch. Toxicol. 2009, 83:87-94.
21. Jordan J., d'Arcy Doherty M., Cohen G.M. Effects of glutathione depletion on the cytotoxicity of agents toward a human colonic tumour cell line. Br. J. Cancer 1987, 55:627-631.
22. Kachadourian R., Day B.J. Flavonoid-induced glutathione depletion: potential implications for cancer treatment. Free Radic. Biol. Med. 2006, 41:65-76.
23. Kachadourian R., Leitner H.M., Day B.J. Selected flavonoids potentiate the toxicity of cisplatin in human lung adenocarcinoma cells: a role for glutathione depletion. Int. J. Oncol. 2007, 31:161-168.
24. Kars M.D., Iseri O.D., Gunduz U., Molnar J. Reversal of multidrug resistance by synthetic and natural compounds in drug-resistant MCF-7 cell lines. Chemotherapy 2008, 54:194-200.
25. Klein R., Brown D., Turnley A.M. Phenoxodiol protects against Cisplatin induced neurite toxicity in a PC-12 cell model. BMC Neurosci. 2007, 8:61.
26. Kovacic P. Unifying mechanism for anticancer agents involving electron transfer and oxidative stress: clinical implications. Med. Hypotheses 2007, 69:510-516.
27. Kovacic P., Osuna J.A. Mechanisms of anti-cancer agents: emphasis on oxidative stress and electron transfer. Curr. Pharm. Des. 2000, 6:277-309.
28. Lee C.K., Son S.H., Park K.K., Park J.H., Lim S.S., Chung W.Y. Isoliquiritigenin inhibits tumor growth and protects the kidney and liver against chemotherapy-induced toxicity in a mouse xenograft model of colon carcinoma. J. Pharmacol. Sci. 2008, 106:444-451.
29. Leitner H.M., Kachadourian R., Day B.J. Harnessing drug resistance: using ABC transporter proteins to target cancer cells. Biochem. Pharmacol. 2007, 74:1677-1685.
30. Mallery S.R., Clark Y.M., Ness G.M., Minshawi O.M., Pei P., Hohl C.M. Thiol redox modulation of doxorubicin mediated cytotoxicity in cultured AIDS-related Kaposi's sarcoma cells. J. Cell. Biochem. 1999, 73:259-277.
31. Marelli L., Grasso A., Pleguezuelo M., Martines H., Stigliano R., Dhillon A.P., Patch D., Davidson B.R., Sharma D., Rolles K., Burroughs A.K. Tumour size and differentiation in predicting recurrence of hepatocellular carcinoma after liver transplantation: external validation of a new prognostic score. Ann. Surg. Oncol. 2008, 15:3503-3511.
32. Mena S., Benlloch M., Ortega A., Carretero J., Obrador E., Asensi M., Petschen I., Brown B.D., Estrela J.M. Bcl-2 and glutathione depletion sensitizes B16 melanoma to combination therapy and eliminates metastatic disease. Clin. Cancer Res. 2007, 13:2658-2666.
33. Muller I., Niethammer D., Bruchelt G. Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review). Int. J. Mol. Med. 1998, 1:491-494.
34. O'Connor R. The pharmacology of cancer resistance. Anticancer Res. 2007, 27:1267-1272.
35. O'Dwyer P.J., Hamilton T.C., LaCreta F.P., Gallo J.M., Kilpatrick D., Halbherr T., Brennan J., Bookman M.A., Hoffman J., Young R.C., Comis R.L., Ozols R.F. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J. Clin. Oncol. 1996, 14:249-256.
36. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 2006, 580:2903-2909.
37. Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem. 2006, 13:1859-1876.
38. Priebe W., Krawczyk M., Kuo M.T., Yamane Y., Savaraj N., Ishikawa T. Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump. Biochem. Biophys. Res. Commun. 1998, 247:859-863.
39. Psotova J., Chlopcikova S., Miketova P., Hrbac J., Simanek V. Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part III. Apigenin, baicalelin, kaempherol, luteolin and quercetin. Phytother. Res. 2004, 18:516-521.
40. Rahman I., Kode A., Biswas S.K. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat. Protoc. 2006, 1:3159-3165.
41. Ramos S. Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol. Nutr. Food Res. 2008, 52:507-526.
42. Schnelldorfer T., Gansauge S., Gansauge F., Schlosser S., Beger H.G., Nussler A.K. Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells. Cancer 2000, 89:1440-1447.
43. Singal P.K., Li T., Kumar D., Danelisen I., Iliskovic N. Adriamycin-induced heart failure: mechanism and modulation. Mol. Cell. Biochem. 2000, 207:77-86.
44. Sinha B.K., Katki A.G., Batist G., Cowan K.H., Myers C.E. Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells. Biochem. Pharmacol. 1987, 36:793-796.
45. Sinha B.K., Mimnaugh E.G., Rajagopalan S., Myers C.E. Adriamycin activation and oxygen free radical formation in human breast tumor cells: protective role of glutathione peroxidase in adriamycin resistance. Cancer Res. 1989, 49:3844-3848.
46. Smith T.K., Ikeda Y., Fujii J., Taniguchi N., Meister A. Different sites of acivicin binding and inactivation of gamma-glutamyl transpeptidases. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:2360-2364.
47. Soriano A.F., Helfrich B., Chan D.C., Heasley L.E., Bunn P.A., Chou T.C. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res. 1999, 59:6178-6184.
48. Takayanagi S., Kataoka T., Ohara O., Oishi M., Kuo M.T., Ishikawa T. Human ATP-binding cassette transporter ABCC10: expression profile and p53-dependent upregulation. J. Exp. Ther. Oncol. 2004, 4:239-246.
49. Toh S., Wada M., Uchiumi T., Inokuchi A., Makino Y., Horie Y., Adachi Y., Sakisaka S., Kuwano M. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am. J. Hum. Genet. 1999, 64:739-746.
50. Toyoda Y., Hagiya Y., Adachi T., Hoshijima K., Kuo M.T., Ishikawa T. MRP class of human ATP binding cassette (ABC) transporters: historical background and new research directions. Xenobiotica; the fate of foreign compounds in biological systems 2008, 38:833-862.
51. Ueda K., Cardarelli C., Gottesman M.M., Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. U.S.A. 1987, 84:3004-3008.
52. Velsor L.W., Kariya C., Kachadourian R., Day B.J. Mitochondrial oxidative stress in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am. J. Respir. Cell Mol. Biol. 2006, 35:579-586.
53. Walle U.K., Galijatovic A., Walle T. Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Biochem. Pharmacol. 1999, 58:431-438.
54. Wijnholds J., Evers R., van Leusden M.R., Mol C.A., Zaman G.J., Mayer U., Beijnen J.H., van der Valk M., Krimpenfort P., Borst P. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat. Med. 1997, 3:1275-1279.
55. Yang D.I., Chen S.D., Yin J.H., Hsu C.Y. S-nitrosoglutathione and hypoxia-inducible factor-1 confer chemoresistance against carbamoylating cytotoxicity of BCNU in rat C6 glioma cells. Ann. N. Y. Acad. Sci. 2005, 1042:229-234.